BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
Barclays maintains overweight on Lupin
Suprax to face generic competition from Aurobindo Pharma. Suprax accounted for around 8 per cent of sales for Lupin. See a negative impact of 2-3 per cent on FY16 EPS estimates due to the launch of generic version of Suprax by Aurobindo Pharma. Maintain Lupin as our global top pick.